Retrospective Study
Copyright ©The Author(s) 2022.
World J Orthop. Mar 18, 2022; 13(3): 278-288
Published online Mar 18, 2022. doi: 10.5312/wjo.v13.i3.278
Table 2 Demographic, clinical and outcome data of subgroup B patients treated with a combined technology Masquelet induced membrane technique + Ilizarov bone transport
Patient
Age (yr), Gender
Neurofibromatosis
Type (number) of previous surgeries
Paley CPT Type
Shortening/Bone defect (cm)
Joint Function
Regenerate/nonunion consolidation completeness
Consolidation time (mo)
Complications (Paley classification)
Follow-up (mo)
Residual limb length discrepancy (cm)
Recurrence/Further surgery
СPT-14, MI type-4C5/3Full+/+7Regenerate deformity243Refracture
СPT -23, M-EF (1); Nail (1)4C5/2Ankle stiffness+/+9Pin-tract infection363 Refracture
СPT -315, FI typeMore than 10 including EF, Nail4A15/3Ankle stiffness+/+10Pin-tract infection1212
СPT -45, MI type-4B3/1.5Full+/-7.5Pin-tract infection243Ilizarov monofocal compression
СPT -58, FI typePlate (1); Nail (2); EF (4)4B10/3Ankle ankylosis+/+9 -3612 Twice Ilizarov lengthening by 6 cm
СPT -64, MI typeEF (1); Autograft (1)4C5/1.5Full-/-8 Ischemic regenerate246 Bone defect, rejected further treatment
СPT -76, F-EF and allograft (2)4A5/5Full+/+13.5 Ischemic regenerate 125 -
СPT -86, F-Plate (1); Nail (2); EF (4)4B4/3Full+/+7 Pin-tract infection242 Refracture
СPT -94, F-Plate (1); Nail (2); EF (4)4A2/2Ankle stiffness+/+8 -362 Refracture